Key Points
- Alphatec EVP David Sponsel sold 163,452 shares on March 11 at an average price of $12.52 for about $2.05 million, cutting his position by 24.45% to 504,932 shares (he also sold 60,425 shares on Feb. 5 at $13.79).
- Quarterly results beat estimates: Alphatec reported $0.06 EPS versus $0.04 expected and revenue of $212.93 million, up 20.4% year‑over‑year.
- Market and analyst context: The stock trades near $12.28 with a 1‑year range of $8.81–$23.29, and analysts have an average rating of "Moderate Buy" with an average target of $22.82 (10 Buys, 1 Hold, 1 Sell).
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 163,452 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total transaction of $2,046,419.04. Following the transaction, the executive vice president owned 504,932 shares in the company, valued at $6,321,748.64. The trade was a 24.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
David Sponsel also recently made the following trade(s):
- On Thursday, February 5th, David Sponsel sold 60,425 shares of Alphatec stock. The stock was sold at an average price of $13.79, for a total transaction of $833,260.75.
Alphatec Price Performance
Shares of ATEC opened at $12.28 on Friday. The firm has a market capitalization of $1.86 billion, a PE ratio of -12.93 and a beta of 1.02. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. Alphatec Holdings, Inc. has a 1-year low of $8.81 and a 1-year high of $23.29. The company's fifty day moving average price is $15.11 and its 200-day moving average price is $16.88.
Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The firm had revenue of $212.93 million during the quarter, compared to analysts' expectations of $212.67 million. During the same quarter last year, the business earned ($0.23) EPS. The business's revenue was up 20.4% on a year-over-year basis. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.
Analyst Upgrades and Downgrades
ATEC has been the subject of a number of research reports. Stifel Nicolaus decreased their target price on Alphatec from $24.00 to $20.00 and set a "buy" rating for the company in a report on Monday, March 9th. HC Wainwright reiterated a "buy" rating and issued a $24.00 price target on shares of Alphatec in a report on Monday, January 12th. Barclays raised their price target on shares of Alphatec from $23.00 to $27.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 7th. Weiss Ratings restated a "sell (e+)" rating on shares of Alphatec in a research note on Monday, December 29th. Finally, Morgan Stanley set a $23.00 price objective on shares of Alphatec in a report on Tuesday, December 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Alphatec presently has an average rating of "Moderate Buy" and an average target price of $22.82.
Read Our Latest Stock Analysis on ATEC
Institutional Trading of Alphatec
Several hedge funds and other institutional investors have recently bought and sold shares of ATEC. Vanguard Group Inc. raised its position in Alphatec by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,883,626 shares of the medical technology company's stock valued at $144,831,000 after acquiring an additional 68,568 shares in the last quarter. American Century Companies Inc. boosted its position in Alphatec by 2.6% in the 3rd quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company's stock worth $92,133,000 after purchasing an additional 159,330 shares in the last quarter. Morgan Stanley boosted its position in Alphatec by 22.0% in the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company's stock worth $91,333,000 after purchasing an additional 784,191 shares in the last quarter. State Street Corp grew its stake in shares of Alphatec by 6.4% during the 4th quarter. State Street Corp now owns 2,889,240 shares of the medical technology company's stock worth $60,790,000 after purchasing an additional 174,287 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Alphatec by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 2,828,026 shares of the medical technology company's stock worth $59,511,000 after purchasing an additional 32,465 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.
Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
